Defitelio
Payments companies reported to CMS as associated with Defitelio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Defitelio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Defitelio
These are the largest totals companies reported as associated with Defitelio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Revati Shreeniwas | Stanford, CA | Pulmonary Disease | $200,200.00 |
| Mitchell Cairo | Hawthorne, NY | Pediatric Hematology-Oncology | $148,740.10 |
| Yasser Khaled | Orlando, FL | Medical Oncology | $95,895.61 |
| Usama Gergis | Allentown, PA | Hematology & Oncology | $94,366.12 |
| David Margolis | Thiensville, WI | Pediatric Hematology-Oncology | $66,268.50 |
| Frederick Goldman | Birmingham, AL | Pediatric Hematology-Oncology | $58,113.40 |
| Nancy Kuntz | Orange, CA | Pediatrics (Nurse Practitioner) | $55,868.08 |
| Micalena Perkins | Burley, ID | Nurse Practitioner | $43,089.44 |
| Troy Quigg | Grand Rapids, MI | Pediatric Hematology-Oncology | $40,607.60 |
| Stanton Goldman | Dallas, TX | Pediatric Hematology-Oncology | $39,496.84 |
Prescribed Defitelio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.